CONDUIT PHARMACEUTICAL

Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline

04 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

01 11 2024 15:45:00 提供 Nasdaq GlobeNewswire

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

28 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

12 8 2024 06:00:00 提供 Nasdaq GlobeNewswire

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

08 8 2024 05:30:00 提供 Nasdaq GlobeNewswire

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

16 7 2024 06:30:00 提供 Nasdaq GlobeNewswire

Conduit Pharmaceuticals to Join Russell 3000® Index

13 6 2024 07:00:00 提供 Nasdaq GlobeNewswire

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

19 3 2024 06:00:00 提供 Nasdaq GlobeNewswire

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub

11 3 2024 06:00:00 提供 Nasdaq GlobeNewswire

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

31 1 2024 07:30:00 提供 Nasdaq GlobeNewswire

Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference

02 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656

11 10 2023 07:30:00 提供 Nasdaq GlobeNewswire